Research programme: cathepsin K inhibitors - GlaxoSmithKline

Drug Profile

Research programme: cathepsin K inhibitors - GlaxoSmithKline

Alternative Names: Cathepsin K inhibitors research programme - GlaxoSmithKline

Latest Information Update: 23 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoarthritis; Osteoporosis

Most Recent Events

  • 23 Jan 2008 No development reported - Preclinical for Osteoarthritis in USA (PO)
  • 23 Jan 2008 No development reported - Preclinical for Osteoporosis in USA (PO)
  • 21 Sep 2005 Data presented at the 230th American Chemical Society National Meeting - (230th-ACS-2005) have been added to the pharmacokinetics and Musculosceletal disorders sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top